Valeant Pharmaceuticals Intl. v. Mylan Pharmaceuticals Inc., No. 18-2097 (Fed. Cir. Apr. 8, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Mylan Pharmaceuticals Inc., Mylan Inc., and Mylan Laboratories Ltd. (collectively, “Mylan”) appeal from the U.S. District Court for the District of New Jersey’s grant of summary judgment that claim 8 of U.S. Patent 8,552,025 (“the ’025 patent”) is not invalid. Valeant Pharm. Int’l, Inc. v. Mylan Pharm., Inc. , No. 2:15-cv-08180 (SRC), 2018 WL 2023537 (D.N.J. May 1, 2018) (“Decision”). For the reasons detailed below, we reverse and remand. B ACKGROUND Valeant owns the ’025 patent, which claims stable me- thylnaltrexone pharmaceutical preparations.